Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
Abstract The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer patients who received long-term trastuzumab were in...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-35715-2 |